Citadel Advisors
CRBP icon

Citadel Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Citadel Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$109K Buy
+11,600
New +$97.7K ﹤0.01% 11929
2025
Q3 		– Sell
-21,700
Closed -$150K – 12924
2025
Q2 		$150K Sell
21,700
-200
-0.9% -$1.45K ﹤0.01% 10961
2025
Q1 		$116K Buy
21,900
+4,400
+25% +$38.8K ﹤0.01% 11251
2024
Q4 		$207K Sell
17,500
-46,600
-73% -$781K ﹤0.01% 10402
2024
Q3 		$1.32M Buy
64,100
+53,700
+516% +$2.75M ﹤0.01% 6295
2024
Q2 		$471K Buy
10,400
+900
+9% +$37.9K ﹤0.01% 8175
2024
Q1 		$373K Buy
+9,500
New +$234K ﹤0.01% 9000
2023
Q1 		– Sell
-160
Closed -$530 – 14813
2022
Q4 		$530 Buy
+160
New +$616 ﹤0.01% 14633
2022
Q3 		– Sell
-493
Closed -$4K – 12745
2022
Q2 		$4K Sell
493
-937
-66% -$9.06K ﹤0.01% 12692
2022
Q1 		$23K Sell
1,430
-300
-17% -$3.98K ﹤0.01% 13207
2021
Q4 		$32K Buy
1,730
+603
+54% +$16.3K ﹤0.01% 13452
2021
Q3 		$34K Sell
1,127
-4,683
-81% -$185K ﹤0.01% 13523
2021
Q2 		$319K Buy
5,810
+1,650
+40% +$91.6K ﹤0.01% 11116
2021
Q1 		$246K Buy
4,160
+953
+30% +$62.6K ﹤0.01% 11268
2020
Q4 		$120K Sell
3,207
-5,440
-63% -$203K ﹤0.01% 10099
2020
Q3 		$467K Buy
8,647
+5,337
+161% +$967K ﹤0.01% 7416
2020
Q2 		$833K Buy
+3,310
New +$669K ﹤0.01% 6170
2020
Q1 		– Sell
-457
Closed -$75K – 9650
2019
Q4 		$75K Buy
457
+80
+21% +$11.8K ﹤0.01% 8653
2019
Q3 		$55K Sell
377
-386
-51% -$67.2K ﹤0.01% 8674
2019
Q2 		$159K Sell
763
-5,857
-88% -$1.25M ﹤0.01% 8326
2019
Q1 		$1.38M Buy
6,620
+2,733
+70% +$603K ﹤0.01% 5040
2018
Q4 		$681K Buy
3,887
+2,160
+125% +$431K ﹤0.01% 5925
2018
Q3 		$391K Buy
1,727
+627
+57% +$101K ﹤0.01% 7117
2018
Q2 		$167K Buy
1,100
+187
+20% +$34K ﹤0.01% 8015
2018
Q1 		$167K Buy
913
+306
+50% +$68.7K ﹤0.01% 7473
2017
Q4 		$129K Buy
+607
New +$130K ﹤0.01% 7331
2017
Q3 		– Sell
-557
Closed -$105K – 7590
2017
Q2 		$105K Sell
557
-926
-62% -$182K ﹤0.01% 6885
2017
Q1 		$367K Buy
+1,483
New +$364K ﹤0.01% 5558

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's CRBP Position: Q1 2026 in Review

Citadel Advisors reduced its Corbus Pharmaceuticals (CRBP) stake by 14% in Q1 2026, selling an estimated $978K and leaving 727,060 shares worth $6.83M. The position accounts for ﹤0.01% of the portfolio, ranked #3848.

Citadel Advisors first reported a position in CRBP in Q4 2015 and has held it in 26 quarters since. The position peaked at $15.1M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Citadel Advisors held 727,060 shares of Corbus Pharmaceuticals worth $6.83M as of Q1 2026.
  • Citadel Advisors sold 116,133 Corbus Pharmaceuticals shares in Q1 2026, an estimated $978K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3848 holding.
  • Citadel Advisors first reported a position in Corbus Pharmaceuticals in Q4 2015 and has held it in 26 quarters since.
  • Citadel Advisors's Corbus Pharmaceuticals position peaked at $15.1M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.